A critical review of the literature on the effects of antihypertensive drugs on the fetus in pregnant women is presented. The survey covers the alpha-adrenergic receptor agonists, beta-blockers including topical eye medications, alpha-beta blockers, calcium antagonists, diuretics, and angiotensin-converting enzyme (ACE) inhibitors. The lack of data on angiotensin II receptor blockers is noted although effects are considered to be similar to those reported with ACE inhibitors and therefore to be avoided. Analysis of the literature underKeywords: hypertension in pregnancy; antihypertensive drugs and fetus; teratology and antihypertensive drugs
Introduction
The use of antihypertensive drugs in pregnant women with chronic hypertension remains controversial in light of the usual fall in blood pressure that occurs during the first half of pregnancy, 1 and the probable deleterious effects on fetal growth and development of antihypertensive drugs and treatment-induced blood pressure declines. 2, 3 Whether or not pre-eclampsia develops, the presence of proteinuria early in pregnancy puts women with chronic hypertension at higher risk for adverse neonatal outcomes. 4 Rey and Couturier 5 retrospectively evaluated the course of 298 pregnant women with chronic hypertension whose antihypertensive medications had been discontinued or reduced in doses early in pregnancy. Neither superimposed preeclampsia, preterm delivery, abrupto placentae, nor perinatal death was less frequent than in treated women. Although placebo-controlled trials on antihypertensive drug treatment in pregnancy are lacking, considerable data have accumulated on this topic (Table 1) . 
Methyldopa
On the basis of reports of stable uteroplacental blood flow and fetal haemodynamics, 6 methyldopa has become the preferred agent as first-line therapy and has been used most commonly in randomised trials. 7 It is considered the safest and most efficacious antihypertensive drug for use in pregnancy and is therefore recommended by all working groups. 8 Kirsten and colleagues 9 consider it the only acceptable drug during the first trimester of pregnancy.
Alpha-and beta-adrenergic blocking agents -labetalol
When methyldopa causes somnolence and cannot be tolerated, alternatives such as the alpha-betaadrenergic blocking agent, labetalol, may be used. Clinical experience with labetalol is extensive and it is among the most widely used antihypertensive drugs in pregnancy. 10 Blood pressure and proteinuria fell significantly in a placebo controlled trial of labetalol in a cohort of 144 women with pregnancy-induced mild and moderate hypertension. However, gestation was not significantly prolonged and measures of clinical outcome were not significantly altered in these women. 11 Possible advantages and no evidence of disadvantages for the fetus were reported in another trial with labetalol, this time a double-blind controlled study in 152 women. 12 Thus labetalol is generally not considered to adversely affect the fetus during the third trimester of pregnancy, and is commonly used to treat hypertension at that stage. 
Beta-adrenergic blocking agents
The beta-adrenergic receptor antagonists, including metoprolol and atenolol, are also considered safe and effective in late gestation, but have been reported to cause some fetal problems when given in early or mid-gestation. 13, 14 Beta-blockers, especially atenolol, have been linked with fetal growth retardation when given early in pregnancy. 15 A largescale retrospective study of atenolol in 78 pregnancies showed that the drug was associated with fetal growth retardation, particularly when it was given early in pregnancy and continued for a long time. 16 These authors urge avoiding atenolol in the early stages of pregnancy and exercising caution at later stages. A randomised trial in which atenolol or placebo was given before 24 weeks of gestation to normotensive pregnant women with high cardiac output in an attempt to prevent pre-eclampsia revealed similar results, namely smaller babies than those getting placebo. 17 Churchill et al, 18 on the other hand, found little difference in fetal growth between women who began atenolol in the second trimester, women on other antihypertensive drugs, and those using no medication.
A basic concern of these and other authors is the level at which blood pressure should be treated and to which blood pressure should be lowered in pregnancy. Magee 19 raises this question, noting that many factors are likely to affect fetal growth other than maternal blood pressure. He points to the connection between antihypertensive treatment and the goal of best perinatal outcome, which remains to be addressed. An international multicentre randomised controlled trial, Control of Hypertension in Pregnancy and small for gestational age (SGA) Infants (CHIPS), is currently being designed to answer these questions. 20 Since topical eye medications are absorbed through the nasopharyngeal mucosa and can therefore enter the systemic circulation, beta-blocker eye drops should be avoided in the first trimester of pregnancy. This is especially noteworthy because glaucoma can occur during the second to the fifth decade of life, a time when women are at risk for pregnancy. Indeed, Wagebvoort et al 21 reported a case in which timolol eye drops were associated with bradycardia and arrhythmia in the fetus, a phenomenon observed also in sheep by Van Tetten. 22 The literature on the use of other forms of eye drops, such as betaxolol and levobunolol in pregnant women, is lacking. 23 
Alpha adrenergic blocking agents
Although prazosin is rarely used in pregnancy, it was recently reported that in the third trimester, fetal concentrations of prazosin are 10-20% of the maternal concentrations, suggesting the possibility that prazosin may affect the fetus. 24 Prazosin has been associated with transverse limb defects in the fetus in a case report. 25 Prazosin taken from day 7 of gestation resulted in limb defects, hypoxic renal damage, and intrauterine death at 20 weeks. These authors 25 attributed the anomalies to drug-induced hypotension in the mother, with resultant diminished uteroplacental blood flow, fetal hypotension and hypoxia. This is only a speculation, and if this were the case, we would expect to see more limb reduction defects in the population treated with antihypertensive drugs than we actually do. One should be cautious about drawing conclusions concerning the adverse effects of drugs on the fetus based on isolated case reports since fetal defects occur in a sporadic case in the general population of pregnant women independent of both hypertension and antihypertensive therapy.
Vasodilators
The potent vasodilator minoxidil 26 has been shown to adversely affect the fetus causing hypertrichosis of the back and extremities in a 38-week-old infant born to a woman administered a daily regimen of minoxidil, captopril and propranolol. Additional pathologic features included dysmorphic facial features, bilateral fifth finger clinodactyly, and an omphalocele containing bowel loops. The hypertrichosis was considered evidence of the transplacental effect of minoxidil, but does not necessarily account for the other pathologic features. The congenital abnormalities might be attributable to an interaction among the three drugs. Animal safety studies 27 of the effects of minoxidil in pregnant rats and rabbits revealed no teratogenic effects in rats when given at 20 and 70 times routine human doses on gestation days 6 to 15, while rabbits given those doses on days 6-18 had smaller litter sizes and higher rates of fetal absorption.
Calcium channel blocking agents
Calcium antagonists generally constitute secondline agents, usually administered late in pregnancy. A small multicentre prospective cohort study of first trimester exposures to calcium channel blockers reported no increase in major teratogenic risk. 28 This study suggests that calcium channel blockers (especially nifedipine and verapamil) do not represent a major teratogenic risk. The prematurity and lower birth weight that have been reported with increased frequency among offspring of patients treated with calcium channel blockers may be due to the serious maternal hypertension and not to the therapy per se. A larger multicentre study randomised 145 pregnant women with mild to moderate hypertension to slow release nifedipine or no treatment. Neither benefit nor harm from the treatment was reported in the 138 women who began treatment in the second trimester. 29 The literature is too sparse, however, to draw any definite conclusions about the safety of calcium channel blockers administered early during pregnancy.
Diuretics
The known association of pre-eclampsia with reduced plasma volume and worse fetal outcome in women with chronic hypertension, who failed to expand their plasma volume appropriately in pregnancy argues against use of diuretics in pregnancy. 30 Indeed, plasma volume expansion was found to be minimal in women using diuretics from early pregnancy compared with normotensive pregnant women. 31 A meta-analysis of nine randomised trials performed by Collins et al, 32 involving more than
Journal of Human Hypertension 7000 pregnant women receiving diuretics, revealed a decrease in the tendency of the women to develop oedema and/or hypertension. Pre-eclampsia, appeared to have been prevented even when oedema was not a diagnostic criterion. This may reflect the blood pressure-lowering action of diuretics. There was little difference in postnatal survival between diuretic treated and untreated groups: stillbirths were about one-third less with treatment, but small numbers made the difference statistically insignificant. There was no increased incidence of adverse fetal effects. Although data concerning the use of diuretics in pregnant women with essential hypertension are sparse, the Working Group Report on High Blood Pressure in Pregnancy, 2000 1 concluded that gestation does not preclude use of diuretics to reduce or control blood pressure in women whose hypertension predated conception or manifested before mid-pregnancy. These safe and efficacious agents, can markedly potentiate the response to other antihypertensive agents, and are not contraindicated in pregnancy except in settings where uteroplacental perfusion is already reduced (pre-eclampsia and intrauterine growth restriction).
Angiotensin-converting enzyme inhibitors
Animal studies have found angiotensin-converting enzyme inhibitors (ACEIs) to be associated with fetal anomalies. Captopril administered to two nearterm pregnant guinea pigs reduced fetal ACE activity below levels seen in control animals, 33 indicating that the drug can adversely affect blood pressure control during both fetal and neonatal life. Administration of enalapril to ewes 34 produced unexpected fetal deaths, skeletal abnormalities, and an unexplained stillbirth. Histological examination of the lungs of this last fetus showed inadequate lung expansion indicative of severe intrapartum asphyxia and/or possibly a surfactant deficiency. When given to lambs and rabbits late in pregnancy, 35 captopril resulted in a high percentage of stillbirths in the former and prolonged gestation in the latter. These studies point to the rapid passage of captopril across the placenta. Captopril in pregnant rabbits in another study 36 reduced blood pressure, slowed uterine blood flow, and drastically decreased uterine vein prostaglandin E (PGE). The importance of PGE synthesis in maintaining uterine blood flow and the survival of the fetus evidenced by these findings raises the possibility that uterine PGE synthesis is dependent on angiotensin II.
Experience with ACEIs in humans confirms much of the data from animal studies. Fiocchi and coworkers, 37 in a letter to the editor in the Lancet, described a case in which captopril was given throughout pregnancy to a 47-year-old hypertensive woman with no untoward events until weeks 32-36, when there was progressive retardation in fetal growth according to imaging and biochemical parameters. This baby was born with no abnormalities despite continuous administration of captopril throughout the pregnancy. With some exceptions, 38 despite early case reports supporting the safety of ACEIs in pregnancy, the literature is generally not in favour of using ACEIs because of associated severe fetal and neonatal disease. 39 A number of reviews and reports addressed to clinical tetralogy counsellors cited oligohydramnios and/or neonatal anuria, pulmonary hydroplasia, mild to severe intrauterine growth retardation, and fetal death associated with ACEIs. Persistent anuria in neonates was attributed to maternal intake of captopril 40 and to a battery of antihypertensive drugs including enalapril. 41 Neonatal renal failure and some dysmorphic features were described following captopril;
42 the death of a child from pulmonary hypoplasia was attributed to oligohydramnios following enalapril; 43 and acute renal failure was reported in a premature newborn following enalapril. 44 Two cases of bone hypocalvaria were reported by Barr and Cohen, 45 one in the fetus of a woman who received captopril and another in a woman who received lisinopril both fetuses had fetopathy with renal tubular dysgenesis and severely underdeveloped calvarial bone. Other cases of underdeveloped calvaria induced by captopril were described by Duminy and Burger 46 and Mheta and Modi. 47 The anomalies described in these cases-fetal and neonatal mortality, neonatal anuria, intrauterine growth retardation,and calvarial hypoplasia-are connected with severe fetal hypotension during the second and third trimester. The morphologic findings and/or signs of fetal growth restriction attest to utero hypotension/hypoxia.
A French group 48 reported fetal death, preterm delivery, and small-for-age newborns in women taking captopril or enalapril during pregnancy, but also noted that in seven cases in which ACEIs were combined with diuretics, perinatal outcome was unremarkable. Brent 39 considered it important to alert physicians to the possibility of fetal and neonatal disease following transplacental passage of captopril, especially since a report suggesting that captopril is not teratogenic 49 raised the likelihood of physicians prescribing it during pregnancy.
Although there is agreement that ACEIs can pose a risk to the fetus, 39 there is controversy over the timing and duration of exposure in relation to fetal risk and the magnitude of the risk during the unsafe stages. While an editorial in The Lancet in 1989 50 cautioned that most of the pregnant women reported in the various studies were also receiving other drugs, there is no question that oligohydramnios, fetal death, neonatal anuria, intrauterine growth retardation and fetal calvarial hypoplasia are direct effects of ACEIs on the fetus. ACEIs are absolutely contraindicated in women with child-bearing potential, based on the evidence of a high degree of morbidity and mortality in fetuses or newborn infants exposed to these drugs during pregnancy. 51, 52 Lip et al 53 further stated that there is no justification to continue using ACEIs once pregnancy is documented, and recommended that they should be stopped or changed to an alternative agent.
Angiotensin II receptor antagonists
Adverse effects of angiotensin II receptor antagonists on fetal kidneys have been documented in rats and sheep, [54] [55] [56] and recent case reports have provided data on their effects on humans. Losartan, hydrochlorothiazide, felodipine and metoprolol given to a 42-year-old woman from the beginning of pregnancy 57 resulted in a baby with varus deformation, of the left foot, clubbed right foot and fixed external rotation of right knee, Potter's facies, and patent ductus arteriosus. This anuric baby died on the 4th postnatal day. Microscopy revealed renal tubular dysgenesis.
In another case, 58 a woman on candesartan gave birth to a baby girl with left sided facial palsy and plexus paresis who was anuric at 24 h postpartum, with steadily rising creatinine that dropped at 1 month of age. The authors suspect that the candesartan was responsible for the acute perinatal renal failure in this case.
Three patients 59 on valsartan at the time of conception delivered babies that showed no congenital abnormalities or evidence of renal dysfunction, one of which had growth retardation. The authors concluded that activation of the AT 1 receptor by angiotensin II plays a role in vascular development and growth, so an AT 1 antagonist should not be given to women already pregnant or planning pregnancy.
Conclusions
The high risk of hypertension, particularly severe hypertension, to the pregnant woman, mandates the use of antihypertensive treatment despite possible detrimental effects on the fetus. While antihypertensive therapy is indicated for maternal benefit, it may also permit prolongation of the pregnancy and thereby improve fetal maturity. However, severely hypertensive women are usually delivered soon after their blood pressure is controlled, since the reduction in uteroplacental blood flow following the quick and dramatic reduction in maternal blood pressure adversely affects the fetus.
Diagnosing any drug-related disorder can be difficult. The relationship between a drug and an effect can be definitively established only by withdrawal of the suspected offending agent and rechallengeclearly out of the question in most cases. Studies that attempt to establish a cause and effect relationship based on clinical data are done on cohorts of varying sizes and are usually very small. The effects of treating severe hypertension in pregnancy have been investigated in only a few placebo-controlled trials. There is a pressing need for well-designed, controlled studies carried out by multidisciplinary teams of obstetricians, hypertension specialists, epidemiologists, and even geneticists. More information about the risks and safety of specific drugs, dosages and combinations should enable the physician to be bolder in attempting to treat this condition which if left unattended, will harm both the mother and fetus.
